This study aimed to investigate the possible role of granulin (GRN) in activating the TLR9-IFN-α pathway in renal tubular epithelial cells (RTECs) and explore clues that RTECs regulate the micro-environment of inflammatory response in lupus nephritis (LN).
Methods
Renal sections from 57 LN patients and 30 non-LN patients were sampled for histological study, and GRN overexpression RTECs were applied for cytological study.
Results
In the histological study, GRN is highly expressed in LN RTECs with tubulointerstitial inflammation (TII) and well co-localized with TLR9. ROC analysis suggested a potential relationship between GRN expression in RTECs and therapeutic response. Moreover, IFN-α also highly expressed in LN RTECs with TII, and the intensity of IFN-α is positively correlated with the co-localization intensity of GRN and TLR9. In the cytological study, LN serum, especially serum from LN with TII, activates the expression of TLR9 in RTECs, and GRN engages the interaction of TLR9 to activate the expression of IFN-α in RTECs. While TLR9 inhibitors can suppress the expression of IFN-α in RTECs, the degree of inhibition is dose-dependent.
Conclusion
The expression of GRN in RTECs is associated with interstitial inflammation and therapeutic response. GRN may mediate the activation of the TLR9-IFN-α pathway in RTECs and involve in the micro-environment of inflammatory response in LN.
Pokroy-ShapiraEGelernterIMoladY. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clin Rheumatol2014; 33: 649–657.
2.
BajemaIMWilhelmusSAlpersCE, et al.Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int2018; 93: 789–796.
3.
TektonidouMGDasguptaAWardMM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol2016; 68: 1432–1441.
4.
TrotterKClarkMRLiarskiVM. Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol2016; 28: 460–467.
5.
AndersHJRovinB. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int2016; 90: 493–501.
6.
BroderAMowreyWBKhanHN, et al.Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Semin Arthritis Rheum2018; 47: 545–551.
7.
HsiehCChangABrandtD, et al.Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res2011; 63: 865–874.
8.
RijninkECTengYKOWilhelmusS, et al.Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol2017; 12: 734–743.
9.
WilsonPCKashgarianMMoeckelG. Interstitial inflammation and interstitial fibrosis and tubularatrophy predict renal survival in lupus nephritis. Clin Kidney J2018; 11: 207–218.
10.
ClarkMRTrotterKChangA. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol2015; 35: 455–464.
11.
Lan-TingHYou-MingCLi-XinW, et al.Clinicopathological factors for tubulointerstitial injury in lupus nephritis. Clin Rheumatol2020; 39: 1617–1626.
12.
CelharTFairhurstAM. Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. Front Pharmacol2014; 5(5): 265.
13.
CrowMK. Type I interferon in the pathogenesis of lupus. J Immunol2014; 192: 5459–5468.
14.
BaoMLiuYJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell2013; 4: 40–52.
15.
Córdoba-DavidGGarcía-GiménezJCardoso Castelo-BrancoR, et al.Crosstalk between TBK1 IKKεand the type I interferon pathway contributes to tubulointerstitial inflammation and kidney tubular injury. Front Pharmacol2022; 13: 987979.
16.
MohammedSVineethaNSJamesS, et al.Regulatory role of SphK 1 in TLR7/9-dependent type I interferon response and autoimmunity. FASEB J2020; 34: 4329–4347.
17.
CastellanoGCafieroCDivellaC, et al.Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther2015; 17: 72.
18.
IwamotoTDorschnerJMSelvarajS, et al.High systemic type I interferon activity is associated with active class III/IV lupus nephritis. J Rheumatol2022; 49: 388–397.
19.
PsarrasAWittmannMVitalEM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol2022; 18: 575–590.
20.
DerESuryawanshiHMorozovPAccelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus AMP RA/SLE Consortium, et al.Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol2019; 20: 915–927.
21.
PapadimitrakiEDTzardiMBertsiasG, et al.Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys:implications for the amplification of the inflammatory response. Lupus2009; 18: 831–835.
22.
BenigniACaroliCLongarettiL, et al.Involvement of renal tubular toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum2007; 56: 1569–1578.
23.
HrabalRChenZJamesS, et al.The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol1996; 3: 747–752.
24.
BatemanABelcourtDBennettH, et al.Granulins, a novel class of peptide from leukocytes. Biochem Biophys Res Commun1990; 173: 1161–1168.
25.
PlowmanGDGreenJMNeubauerMG, et al.The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. J Biol Chem1992; 267: 13073–13078.
26.
ShoyabMMcDonaldVLBylesC, et al.Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. Proc Natl Acad Sci U S A1990; 87: 7912–7916.
27.
BatemanABennettHP. Granulins: the structure and function of an emerging family of growth factors. J Endocrinol1998; 158: 145–151.
28.
DanielRHeZCarmichaelKP, et al.Cellular localization of gene expression for progranulin. J Histochem Cytochem2000; 48: 999–1009.
29.
BhandariVGiaidABatemanA. The complementary deoxyribonucleic acid sequence, tissue distribution, and cellular localization of the rat granulin precursor. Endocrinology1993; 133: 2682–2689.
30.
YinFBanerjeeRThomasB, et al.Exaggerated inflammation, impaired host defense, and neuropathology in progranulindeficient mice. J Exp Med2010; 207: 117–128.
31.
ZhuJNathanCJinW, et al.Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell2002; 111: 867–878.
32.
ParkBButiLLeeS, et al.Granulin is a soluble cofactor for toll-like receptor 9 signaling. Immunity2011; 34: 505–513.
33.
VercellinoMGrifoniSRomagnoloA, et al.Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult Scler2011; 17: 1194–1201.
34.
TangWLuYTianQY, et al.The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science2011; 332: 478–484.
35.
TanakaATsukamotoHMitomaH, et al.Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther2012; 14: R244.
36.
BertsiasGKTektonidouMAmouraZEuropean League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association, et al.Joint European League against rheumatism and European renal associationEuropean Dialysis and Transplant association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis2012; 71: 1771–1782.
37.
YuFWuL-HTanY, et al.Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int2010; 77: 820–829.
38.
LiHTsokosMGBhargavaR, et al.IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. J Clin Invest2021; 131: e142428.
39.
huangLchenYweiL, et al.Levels of granulin in serum and urine of patients with lupus nephritis and its assessment value for disease activity. Guangxi Medical Journal2018; 5: 485–488.
40.
MorescoEMYBeutlerB. Special delivery: granulin brings CpG DNA to Toll-like receptor 9. Immunity2011; 34: 453–455.
41.
GalimbertiDD’AddarioCDell’ossoB, et al.Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurol Sci2013; 34: 899–903.
42.
RademakersREriksenJLBakerM, et al.Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet2008; 17: 3631–3642.
43.
WangWXWilfredBRMadathilSK, et al.miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol2010; 177: 334–345.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
